Epidermolysis Bullosa Dystrophica
📧 Sign up to get email alerts when something new happens for Epidermolysis Bullosa Dystrophica.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-08EMA Authorised: Vyjuvek (Beremagene geperpavec) — Krystal Biotech Netherlands B.V.
The EMA authorises Vyjuvek (beremagene geperpavec) for Epidermolysis Bullosa Dystrophica.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa [EARLY_Phase 1]
This is an early Phase 1 trial evaluating a self-assembled skin substitute for Epidermolysis Bullosa Dystrophica, with the study currently a…
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
A pilot study by ProgenaBiome evaluating the role of gut flora in Epidermolysis Bullosa has been withdrawn. The study covered Epidermolysis …
-
CLINICAL_TRIALS trial_result · 2023-07-10Clinical Trial Update: Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa [Phase 1, Phase 2]
Phase 1/2 clinical trial update for a gene transfer approach targeting recessive dystrophic epidermolysis bullosa has completed with results…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa [Phase 2]
Phase 2 clinical trial of INM-755 (cannabinol) cream for epidermolysis bullosa has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) [Phase 2]
Phase 2 clinical trial of Polyphenon E (epigallocatechin-3-gallate) for epidermolysis bullosa dystrophica has completed.